NVCR - ノボキュア (NovoCure Limited) ノボキュア

 NVCRのチャート


 NVCRの企業情報

symbol NVCR
会社名 NovoCure Ltd (ノボキュア)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ノボキュア(NovoCure Limited)は商業段階の腫瘍学会社である。同社は固形癌細胞分裂を破壊するために特定の周波数に調整された電場を使用するTTFieldsと呼ばれる療法を中心とする癌治療法の開発に従事する。TTFieldsはグリア芽腫(GBM)の治療に使用され、臨床パイプラインを通じて複数の固形腫瘍適応症におけるTTFieldのプログラム検査を進めるために使用される。GBMの臨床的・商業的発展に加えて、TTFieldは脳転移、非小細胞肺癌(NSCLC)、膵臓癌、卵巣癌および中皮腫におけるTTFieldの使用を評価する臨床試験を計画または実施している。TTFieldは、ポータブルな医療機器を通じて提供される。完全な送達システムは、継続的な癌治療を受けながら患者が日々の活動に慣れることができるように設計され、携帯用電界ジェネレータ、トランスデューサアレイ、充電式バッテリ、アクセサリーを含む。   ノボキュアは英国の医療機器メ―カ―。主に固形がん腫瘍の治療向け医療機器の開発に従事する。同社開発の「TTFields」は非侵襲性の腫瘍治療電場システムで、細胞分裂阻止の治療電場を発生させ通常のプロセスを阻害し、がん細胞を死滅する。一般的ながん治療である手術、放射線治療、抗がん剤治療に合わせ、更なる治療法を開発する。本社は英国ジャ―ジ―島。   NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
本社所在地 No. 4 The Forum Grenville Street St. Helier Jersey JE2 4UF GBR
代表者氏名 William F. Doyle ウィリアムF.ドイル
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +44 1534-75-6700
設立年月日 36557
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 495人
url www.novocure.com
nasdaq_url https://www.nasdaq.com/symbol/nvcr
adr_tso
EBITDA EBITDA(百万ドル) -21.49100
終値(lastsale) 48.2
時価総額(marketcap) 4477903392
時価総額 時価総額(百万ドル) 3966.939
売上高 売上高(百万ドル) 217.40900
企業価値(EV) 企業価値(EV)(百万ドル) 3897.179
当期純利益 当期純利益(百万ドル) -93.47700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Novocure Ltd revenues increased 55% to $113.6M. Net loss decreased 8% to $36.2M. Revenues reflect Europe_Middle East_Africa (EMEA) (Region) segment increase from $12.6M to $32.4M United States segment increase of 32% to $79.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.45 to -$0.40.

 NVCRのテクニカル分析


 NVCRのニュース

   Novocure to Report Second Quarter 2020 Financial Results  2020/07/01 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open.
   Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data  2020/06/02 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--A new tool will enable patients to download their Optune usage data without the need for an in-person visit by a Novocure Device Support Specialist.
   NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates  2020/04/30 11:30:10 Zacks Investment Research
NovoCure (NVCR) delivered earnings and revenue surprises of -20.00% and -2.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Novocure Reports First Quarter 2020 Financial Results and Provides Company Update  2020/04/30 10:00:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure reported financial results for the first quarter of 2020 and provided a company update.
   Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I  2020/04/27 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)-- #btsm--Novocure announced that EF-19 post-approval registry trial data will be presented at the AACR 2020 Virtual Annual Meeting I.
   Novocure to Report Second Quarter 2020 Financial Results  2020/07/01 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open.
   Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data  2020/06/02 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--A new tool will enable patients to download their Optune usage data without the need for an in-person visit by a Novocure Device Support Specialist.
   NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates  2020/04/30 11:30:10 Zacks Investment Research
NovoCure (NVCR) delivered earnings and revenue surprises of -20.00% and -2.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Novocure Reports First Quarter 2020 Financial Results and Provides Company Update  2020/04/30 10:00:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure reported financial results for the first quarter of 2020 and provided a company update.
   Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I  2020/04/27 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)-- #btsm--Novocure announced that EF-19 post-approval registry trial data will be presented at the AACR 2020 Virtual Annual Meeting I.
   Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data  2020/06/02 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--A new tool will enable patients to download their Optune usage data without the need for an in-person visit by a Novocure Device Support Specialist.
   NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates  2020/04/30 11:30:10 Zacks Investment Research
NovoCure (NVCR) delivered earnings and revenue surprises of -20.00% and -2.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Novocure Reports First Quarter 2020 Financial Results and Provides Company Update  2020/04/30 10:00:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure reported financial results for the first quarter of 2020 and provided a company update.
   Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I  2020/04/27 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)-- #btsm--Novocure announced that EF-19 post-approval registry trial data will be presented at the AACR 2020 Virtual Annual Meeting I.
   NovoCure (NVCR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release  2020/04/23 16:32:06 Zacks Investment Research
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ノボキュア NVCR NovoCure Limited)

 twitter  (公式ツイッターやCEOツイッターなど)